Figure 6. Synergistic effect of AR-42 and lenalidomide combination therapy in vivo.
A. NOD-SCID mice engrafted with 5 × 106 MM.1S GFP+/Luc+ cells and treated for 3 weeks with vehicle control (Ctrl), AR-42, lenalidomide (Len), or AR-42/Len combination. Representative luminescence images are shown. B. Tumor progression was evaluated by bioluminescence imaging, which showed that the tumor growth was markedly suppressed in AR-42+Len treated mice, compared to control group (Ctrl), or single agent treated mice. C. Analysis of murine BM tumor progression by CD138-GFP+ quantification by flow cytometry. Data represent the mean ± SD of each group of treatment. D. Kaplan-Meier survival curves for mice in each group of treatments. Comparison between the different groups of treatments was made p-values associated with survival are shown in E.